Surgical mediastinal lymph node staging for non-small-cell lung carcinoma

Area of Science:

• Thoracic Surgery
• Surgical Oncology
• Pulmonology

Background:

• Video-assisted mediastinoscopy is the standard for surgical mediastinal staging of non-small-cell lung carcinoma (NSCLC).
• Video-assisted mediastinoscopic lymphadenectomy (VAMLA) is an alternative technique involving lymph node resection, proposed to improve N2 disease detection.
• Existing evidence comparing VAMLA and video-assisted mediastinoscopy is conflicting and limited by small sample sizes.

Purpose of the Study:

• To compare the efficacy of VAMLA versus traditional video-assisted mediastinoscopy for mediastinal staging in NSCLC patients.
• To evaluate the sensitivity and negative predictive value of each technique in detecting N2 disease.

Main Methods:

• A single-center cohort study compared consecutive NSCLC patients undergoing VAMLA (2011-2018) with historical controls who had video-assisted mediastinoscopy (2007-2011).
• Patients with negative staging proceeded to anatomical resection with lymphadenectomy.
• Primary outcomes were sensitivity and negative predictive value for N2 disease detection.

Main Results:

• VAMLA (n=269) demonstrated higher sensitivity (0.82) and negative predictive value (0.96) for N2 disease compared to video-assisted mediastinoscopy (n=118) (0.62 and 0.89, respectively).
• VAMLA resulted in a 64% reduction in unforeseen N2 disease after resection.
• The rate of unforeseen pN2 was lower with VAMLA (4%) versus video-assisted mediastinoscopy (11%).
• VAMLA was associated with a 75% increased risk of complications, though not statistically significant (P=0.36).

Conclusions:

• VAMLA is a preferred technique for invasive mediastinal lymph node assessment in NSCLC staging due to superior sensitivity and negative predictive value.
• Despite improved staging accuracy, VAMLA carries an increased risk of complications.
• Further research may be warranted to optimize VAMLA and mitigate complication risks.